BiomX (PHGE) Q1 2026 earnings summary

Executive summary

• Transitioned from biopharma to defense, security, and critical infrastructure tech after discontinuing phage therapy and deconsolidating BiomX Israel following insolvency proceedings in Q1 2026.

• Acquired ZorroNet (AI-powered security) and 60% of DFSL (LADAR-based detection) in April 2026; formed X Security & Defense as a new subsidiary.

• Management and board were reconstituted, with new CEO and CFO appointed in Q1 2026.

Financial highlights

• Net loss for Q1 2026 was $19.1 million, compared to $7.7 million in Q1 2025, driven by non-cash warrant-related charges and a $1.9 million gain from deconsolidation of BiomX Ltd.

• Operating loss decreased to $1.3 million from $7.8 million year-over-year, mainly due to reversal of stock-based compensation and discontinued R&D.

• Cash, cash equivalents, and restricted cash were $1.2 million as of March 31, 2026, down from $5.0 million at year-end 2025.

• Accumulated deficit increased to $236.0 million as of March 31, 2026.

Outlook and guidance

• Revenues from DFSL and ZorroNet expected to begin in Q2 2026; cash needs will rise as integration and new operations ramp up.

• Management expects current funds and anticipated revenues to fund operations only for several months; substantial doubt exists about ability to continue as a going concern.

• Plans to seek additional capital via equity, debt, or grants; ability to raise funds is subject to market and regulatory conditions.